Logo Pure Precision
U
Newsletter
Contact us
  • Precision Capturing®
    • Precision Capturing® Technology
    • Non-Antibody Purification
    • Antibody Purification
  • Precision Targeting
    • Precision Targeting Technology
    • Protein Drug Conjugates
    • Radio Conjugates
    • Cellular Therapy
    • Multispecific Ligands
  • Pipeline
  • Company
    • Who we are
    • Team
  • News
    • Press
    • Events
    • Publications
  • Career
    • Career
    • Open Positions
  • Contact
  • Precision Capturing®
    • Precision Capturing® Technology
    • Non-Antibody Purification
    • Antibody Purification
  • Precision Targeting
    • Precision Targeting Technology
    • Protein Drug Conjugates
    • Radio Conjugates
    • Cellular Therapy
    • Multispecific Ligands
  • Pipeline
  • Company
    • Who we are
    • Team
  • News
    • Press
    • Events
    • Publications
  • Career
    • Career
    • Open Positions
  • Contact

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines

by NavigoProteins | Feb 8, 2021 | Press

 WALTHAM, Mass., and HALLE (Saale), Germany – February 8, 2021 – Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in...

Navigo Proteins and Repligen Announce Achievement of a Key Milestone in Development of an Affinity Resin for the Purification of COVID-19Vaccines

by NavigoProteins | Aug 4, 2020 | Press

HALLE (Saale), Germany, and WALTHAM, Mass. – October 1, 2020 – Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, and Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on...

Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity Ligands

by NavigoProteins | Apr 27, 2018 | Press

WALTHAM, MA – June 27, 2018– Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced an agreement with Navigo Proteins GmbH (“Navigo”) for the advancement of exclusive novel affinity ligands used in...

UV-Cap GmbH & Co KG acquires Scil Proteins GmbH Scil Proteins GmbH becomes Navigo Proteins GmbH

by NavigoProteins | Jan 12, 2017 | Press

Halle (Saale), Germany – 3rd Feb 2017 – Scil Proteins GmbH, the expert protein engineering company for affinity ligands and targeted carriers, today announced that UV-Cap GmbH & Co KG, Ravensburg, has acquired 100% of the shares of Scil Proteins from Bionet...

ITM and Scil Proteins announce new Partnership for Targeted Radio Conjugates

by NavigoProteins | Jan 3, 2016 | Press

Garching, Germany and Halle, Germany – 24 March 2016 – ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in Affilin®-based protein engineering, today announced they have entered into a...

Recent Posts

  • Technical Assistant Molecular Biology (m/w/d)
  • Scientist Protein Analytics (m/w/d)
  • Ausbildung Kaufmann für Büromanagement (m/w/d)
  • Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
  • Navigo Proteins and Repligen Announce Achievement of a Key Milestone in Development of an Affinity Resin for the Purification of COVID-19Vaccines

Recent Comments

    Navigo Proteins GmbH
    Heinrich-Damerow-Straße 1
    06120 Halle (Saale)
    Germany

    Phone: +49 345 27996-330
    Fax: +49 345 27996-332
    E-Mail: info@navigo-proteins.com

    Precision Capturing®
    Precision Targeting
    Company
    News
    Career
    Contact
    Imprint
    Disclaimer
    Data Protection

    Social Media

    • Follow

    © Navigo Proteins GmbH

    ×
    Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages